Zaynich is a novel antibiotic combination developed by Wockhardt Ltd., consisting of Cefepime (a 4th-generation cephalosporin) and Zidebactam (a β-lactam enhancer). It is specifically designed to combat multidrug-resistant (MDR) and carbapenem-resistant Gram-negative bacteria, including Pseudomonas aeruginosa and Enterobacterales.
Cefepime inhibits bacterial cell wall synthesis, while Zidebactam acts as both a β-lactamase inhibitor and PBP2 binder, enhancing the antibiotic’s activity even against resistant strains.
Clinical trials have shown high cure rates (around 96–97%) in serious infections such as complicated urinary tract infections (cUTIs). The drug demonstrated comparable safety to meropenem and offers a promising alternative for treating infections where traditional antibiotics fail.
Because both components are renally excreted, dose adjustments are required in patients with renal impairment. Zaynich represents a major advancement in antimicrobial therapy after decades, emphasizing the importance of antimicrobial stewardship to prevent future resistance.
What are the future prospects and challenges in discovering next-generation antibiotics like Zaynich?
MBH/AB
Combining Cefepime and Zidebactam, it tackles tough Gram-negative bacteria that outsmart traditional antibiotics, with cure rates up to 97%. 
While promising, careful use and dose adjustments are crucial, especially in patients with kidney issues.